Publications by authors named "K D Rodland"
Article Synopsis
- Despite extensive research on genomic changes in glioblastoma, the survival rate remains under 5% after five years.
- This study aims to broaden the understanding of high-grade glioma by combining various biological analyses (proteomics, metabolomics, etc.) to identify complex regulatory mechanisms involved in tumor growth and progression.
- Results from analysis of 228 tumors indicate significant variability in early-stage changes, but they converge on common outcomes affecting protein interactions and modifications, highlighting PTPN11's crucial role in high-grade gliomas.
Breast Cancer Res
May 2024
Article Synopsis
- Breast cancer is the most common type of cancer and a major cause of death in women, with some types being harder to treat than others.
- The study looked at the differences between a difficult-to-treat type of breast cancer (DTBC) and a more common type (Luminal A) to find out what makes them different.
- Researchers used advanced techniques to analyze tumor samples and found that DTBC tumors have different gene mutations and characteristics, which could help identify ways to improve treatment and predict patient outcomes.
Article Synopsis
- Emerging research highlights how factors in the leukemia microenvironment protect cancer cells from treatments and contribute to drug resistance, signaling the need for targeted therapies in acute myeloid leukemia (AML).
- A study involving around 300 AML patient samples found that higher levels of the cytokine CCL2 correlate with reduced effectiveness of MEK inhibitors, leading to further investigations into the mechanisms behind this resistance.
- The findings suggest that targeting both CCL2 and the MEK pathway can improve treatment responses in AML, proposing a combination therapy as a promising strategy to overcome drug resistance and enhance patient outcomes.
Cell Rep Med
January 2024
Article Synopsis
- Acute myeloid leukemia (AML) is a challenging cancer to treat due to its complex genetic mutations, which often do not predict how well patients will respond to therapy.
- This study combines multiple data types (proteomic, transcriptomic, and drug sensitivity) from 210 AML patients to uncover new disease subtypes and their drug response patterns beyond just genetic mutations.
- The researchers created a model to predict drug responses tailored to these new subtypes, enhancing treatment strategies and potential drug combinations for AML patients.
Cancers (Basel)
September 2023
Article Synopsis
- The study aims to identify proteins that can help determine which individuals are at high risk for developing lung cancer by analyzing bronchial cells from different risk groups.
- Researchers validated 55 candidate proteins associated with lung cancer risk using sensitive techniques in both a smaller and larger group of participants.
- They found that two proteins, ALDH3A1 and AKR1B10, were consistently overexpressed in high-risk individuals, supporting their potential as biomarkers for lung cancer risk assessment.
